What is Kerendia (Finerenone)?
Kerendia (finerenone) is a first-in-class, nonsteroidal mineralocorticoid receptor antagonist (MRA) approved to reduce the risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease associated with type 2 diabetes. 1
Medication Class and Mechanism
Kerendia is a selective, nonsteroidal MRA that differs fundamentally from older steroidal MRAs (spironolactone, eplerenone) in both its pharmacology and clinical profile 2, 3. It works by blocking pathological overactivation of mineralocorticoid receptors driven by aldosterone, which is a key driver of inflammation and CKD progression in diabetic kidney disease 3.
FDA-Approved Indications
Kerendia has two distinct FDA-approved indications 1:
CKD associated with type 2 diabetes: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure
Heart failure with preserved or mildly reduced ejection fraction (LVEF ≥40%): To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits
Clinical Evidence and Benefits
Kidney and Cardiovascular Protection in Diabetic CKD
The FIDELITY pooled analysis (combining FIDELIO-DKD and FIGARO-DKD trials with 13,171 patients) demonstrated that finerenone provides 4:
- 14% reduction in composite cardiovascular outcomes (cardiovascular death, MI, stroke, heart failure hospitalization): HR 0.86,95% CI 0.78-0.95
- 23% reduction in composite kidney outcomes (sustained ≥57% eGFR decrease or kidney failure): HR 0.77,95% CI 0.67-0.88
- 36% reduction in end-stage kidney disease specifically: HR 0.64,95% CI 0.41-0.995
- 29% reduction in heart failure hospitalizations: HR 0.71,95% CI 0.56-0.90
These benefits occurred across the full spectrum of CKD severity in patients with type 2 diabetes and albuminuria 5.
Dosing and Administration
Starting Dose Based on eGFR 1:
- eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily
- eGFR 25-59 mL/min/1.73 m²: Start 10 mg once daily
- eGFR <25 mL/min/1.73 m²: Initiation not recommended
Critical Pre-Treatment Requirements 1:
- Serum potassium must be ≤5.0 mEq/L before starting (FDA label)
- Measure both potassium and eGFR at baseline
Monitoring Protocol 6, 7:
Check potassium at 1 month after initiation, then every 4 months:
- K+ ≤4.8 mEq/L: Increase dose from 10 mg to 20 mg daily (if eGFR stable)
- K+ 4.9-5.5 mEq/L: Continue current dose, monitor every 4 months
- K+ >5.5 mEq/L: Hold finerenone, address hyperkalemia with dietary/medication adjustments, restart at 10 mg when K+ ≤5.0 mEq/L
Place in Therapy According to Guidelines
KDIGO 2024 Recommendations 6:
Finerenone is suggested for adults with type 2 diabetes, eGFR >25 mL/min/1.73 m², normal potassium, and albuminuria (>30 mg/g) despite maximum tolerated RAS inhibitor dose (Grade 2A).
The guidelines emphasize that nonsteroidal MRAs are most appropriate for patients at high risk of CKD progression and cardiovascular events demonstrated by persistent albuminuria despite standard-of-care therapies 6.
Layered Treatment Approach 6, 7:
Finerenone can be added to both RAS inhibitors and SGLT2 inhibitors for comprehensive cardiorenal protection. The 2025 ADA Standards note that finerenone, SGLT2 inhibitors, and GLP-1 RAs can be used interchangeably or together, with clinicians using best judgment for sequencing 4.
Safety Profile
Hyperkalemia Risk
The most significant adverse effect is hyperkalemia 8, 5:
- Incidence: 10.8% with finerenone vs. 5.3% with placebo
- Discontinuation rate: Only 1.2% stopped due to hyperkalemia in clinical trials
- No deaths related to hyperkalemia occurred in the pivotal trials 8
This represents a substantially lower hyperkalemia risk compared to steroidal MRAs like spironolactone, which showed 26.4% hyperkalemia incidence vs. 17.2% with finerenone in comparative real-world data 9.
Comparative Safety
Real-world evidence suggests finerenone is associated with 9:
- Lower all-cause mortality: aHR 0.31 vs. spironolactone
- Lower major adverse cardiovascular events: aHR 0.74
- Lower major adverse kidney events: aHR 0.47
- Significantly less hyperkalemia than spironolactone
Key Clinical Pearls
Patient Selection: Prioritize finerenone for patients with type 2 diabetes and CKD who have persistent albuminuria despite RAS inhibitor therapy, particularly those at high cardiovascular risk 6.
Combination Therapy: Finerenone provides additive benefits when combined with SGLT2 inhibitors—only 4.5% of FIDELIO-DKD participants were on SGLT2 inhibitors, suggesting most benefit data comes from patients not yet on these agents 8, 5.
Potassium Management: The key to successful finerenone use is proactive potassium monitoring and dose adjustment rather than automatic discontinuation. Most hyperkalemia can be managed with dietary counseling and medication adjustments 6, 7.
Contraindications: Exclude patients with heart failure with reduced ejection fraction and uncontrolled hypertension, as these were exclusion criteria in the cardiovascular outcome trials 5.